FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg given twice-daily) achieving a 76% PASI 75 response – 78.6% clearance of psoriasis skin lesions – at 52 weeks.
In BE RADIANT bimekizumab performed better than Cosentyx at achieving complete clearance of skin lesions – known as a PASI 100 response ... marketed IL-23 drug Skyrizi (risankizumab) also ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback